BioCentury
ARTICLE | Clinical News

Abicipar pegol: Phase II data

October 24, 2016 7:00 AM UTC

The double-blind, sham-controlled, U.S. Phase II PALM trial in 151 DME patients showed that 1 mg intravitreal abicipar pegol every 8 weeks, 2 mg abicipar pegol every 8 weeks and 2 mg abicipar pegol ev...